Oral budesonide for maintenance of remission of Crohn's disease: A pooled safety analysis

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 6, 2009, Pages 643-653

  Lichtenstein, G R ^a   Bengtsson, B ^b   Hapten White, L ^b   Rutgeerts, P ^c  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b ASTRAZENECA R AND D   (Sweden)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; PLACEBO;

ABDOMINAL PAIN; ACNE; ADRENAL FUNCTION; ADRENAL INSUFFICIENCY; ADULT; ALOPECIA; ANKLE EDEMA; ARTERY EMBOLISM; ARTHRITIS; ARTICLE; BACKACHE; BACTERIAL INFECTION; BONE NECROSIS; BUFFALO HUMP; CATARACT; CENTRAL NERVOUS SYSTEM DISEASE; CHOLELITHIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CUSHING SYNDROME; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ECCHYMOSIS; EDEMA; ENDOCRINE DISEASE; ERYTHEMA NODOSUM; FATIGUE; FEMALE; FRACTURE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HERPES ZOSTER; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; INSOMNIA; LABORATORY TEST; LUNG ABSCESS; MAJOR CLINICAL STUDY; MALE; MASTOIDITIS; MELENA; MENSTRUATION DISORDER; MENTAL DISEASE; MENTAL INSTABILITY; MOON FACE; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASE; MYALGIA; MYCOSIS; NAUSEA; OSTEOPOROSIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; RUBELLA; SEPSIS; SIDE EFFECT; SINUSITIS; SKIN APPENDAGE DISEASE; SKIN MANIFESTATION; SKIN STRIAE; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; UNPLANNED PREGNANCY; URINARY TRACT DISEASE; UROLITHIASIS; URTICARIA; VIRUS INFECTION; VISUAL DISORDER; VOMITING;

ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 60349125534     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03891.x     Document Type: Article

References (31)

1. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006 130 : 935 9.
2. Yang YX, Lichtenstein GR. Corticosteroids in Crohn's disease. Am J Gastroenterol 2002 97 : 803 23.
3. Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf 2000 23 : 429 48.
4. Singleton JW, Law DH, Kelley ML Jr., Mekhjian HS, Sturdevant RA. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 1979 77 : 870 82.
5. Edsbacker S, Andersson P, Lindberg C, Paulson J, Ryrfeldt A, Thalen A. Liver metabolism of budesonide in rat, mouse, and man. Comparative aspects. Drug Metab Dispos 1987 15 : 403 11.
6. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994 331 : 836 41.
7. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997 41 : 209 14.
8. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998 339 : 370 4.
9. Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002 97 : 1748 54.
10. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994 331 : 842 5.
11. Sandborn WJ, Feagan BG. Review article: mild to moderate Crohn's disease - defining the basis for a new treatment algorithm. Aliment Pharmacol Ther 2003 18 : 263 77.
12. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006 55 (Suppl. 1 i16 35.
13. Sandborn WJ, Lofberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 2005 100 : 1780 7.
14. Schoon EJ, Bollani S, Mills PR, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol 2005 3 : 113 21.
15. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 1996 110 : 45 51.
16. Ferguson A, Campieri M, Doe W, Persson T, Nygard G. Oral budesonide as maintenance therapy in Crohn's disease - results of a 12-month study. Global Budesonide Study Group. Aliment Pharmacol Ther 1998 12 : 175 83.
17. Lofberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut 1996 39 : 82 6.
18. Hellers G, Cortot A, Jewell D, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology 1999 116 : 294 300.
19. Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther 2005 21 : 363 71.
20. Summers RW, Switz DM, Sessions JT Jr., et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979 77 : 847 69.
21. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984 86 : 249 66.
22. Smith RC, Rhodes J, Heatley RV, et al. Low dose steroids and clinical relapse in Crohn's disease: a controlled trial. Gut 1978 19 : 606 10.
23. Freedman VA, Aykan H, Kleban MH. Asking neutral versus leading questions: implications for functional limitation measurement. J Aging Health 2003 15 : 661 87.
24. Sutherland LR, Martin F, Bailey RJ, et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 1997 112 : 1069 77.
25. Thomson AB, Wright JP, Vatn M, et al. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease. Aliment Pharmacol Ther 1995 9 : 673 83.
26. Mantzaris GJ, Petraki K, Sfakianakis M, et al. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease. Clin Gastroenterol Hepatol 2003 1 : 122 8.
27. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995 37 : 674 8.
28. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000 342 : 1627 32.
29. Andus T, Gross V, Caesar I, et al. Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial. Dig Dis Sci 2003 48 : 373 8.
30. Blanchard JF, Bernstein CN, Wajda A, Rawsthorne P. Small-area variations and sociodemographic correlates for the incidence of Crohn's disease and ulcerative colitis. Am J Epidemiol 2001 154 : 328 35.
31. Magro F, Dinis-Ribeiro M, Araujo FM, et al. High prevalence of combined thrombophilic abnormalities in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2003 15 : 1157 63.